Evidence map›Paper›PMID 37322287›Full record

ReviewMolecular neurobiology2023

H

Weizhuo Lu, Jiyue Wen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Total Flavones ofCurrent issues in molecular biology · 2025
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Weizhuo LuMedical Branch, Hefei Technology College, Hefei, China.
Jiyue WenDepartment of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China. wenjiyue139@aliyun.com.ORCID http://orcid.org/0000-0002-7602-1727
Anhui Medical University · CNHefei University of Technology · CN

Funding

Natural Science Foundation of Colleges and Universities in Anhui Province in 2020 KJ2020A0144Natural Science Foundation of Colleges and Universities in Anhui Province in 2020 KJ2020A0976
6 · The paper itself

Abstract

Ischemic stroke is one of the main reasons of disability and death. Stroke-induced functional deficits are mainly due to the secondary degeneration of the white matter characterized by axonal demyelination and injury of axon-glial integrity. Enhancement of the axonal regeneration and remyelination could promote the neural functional recovery. However, cerebral ischemia-induced activation of RhoA/Rho kinase (ROCK) pathway plays a crucial and harmful role in the process of axonal recovery and regeneration. Inhibition of this pathway could promote the axonal regeneration and remyelination. In addition, hydrogen sulfide (H

Indexed as

Ischemic StrokeRemyelinationStrokeAxonsCell DifferentiationHumansNeurogliaOligodendrogliarho-Associated Kinasesrho-Associated KinasesAxonal recoveryH2SIschemic strokeRemyelinationRhoA/ROCK pathway

Identifiers

PMID37322287
OpenAlexW4380740441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.